Page
%P
-
Article
Rituximab (Mabthera™, rituxan™) in patients with recurrent indolent lymphoma
The objective of this multiinstitutional study was to evaluate the safety and efficacy of rituximab at standard four weekly doses in patients with recurrent indolent lymphoma. Thirty-eight patients entered int...